Page last updated: 2024-08-24

lamivudine and Clerambault Syndrome

lamivudine has been researched along with Clerambault Syndrome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baijnath, S; Govender, T; Kruger, HG; Mdanda, S; Naicker, T; Ntshangase, S; Singh, SD	1
Crespo, M; Esteban, H; Gutiérrez, F; Hernández-Quero, J; Iribarren, JA; Mariño, A; Pasquau, J; Pérez-Molina, JA; Pérez-Valero, I; Rivero, A; Rubio, R; Santos, J; Sanz, J; Terrón, A	1
Halquist, MS; Hauser, KF; Jones, AM; Kashuba, ADM; Kim, WK; Knapp, PE; Leibrand, CR; Masuda, QN; McRae, M; Paris, JJ	1

Trials

1 trial(s) available for lamivudine and Clerambault Syndrome

Article	Year
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. The Journal of antimicrobial chemotherapy, 2018, 09-01, Volume: 73, Issue:9 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir	2018

Article

Year

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.

The Journal of antimicrobial chemotherapy, 2018, 09-01, Volume: 73, Issue:9

Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir

2018

Other Studies

2 other study(ies) available for lamivudine and Clerambault Syndrome

Article	Year
Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay and drug development technologies, 2019, Volume: 17, Issue:7 Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Female; HIV Infections; Injections, Intraperitoneal; Lamivudine; Neurocognitive Disorders; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tissue Distribution; Zidovudine	2019
HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. Journal of neurovirology, 2019, Volume: 25, Issue:4 Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Corpus Striatum; Dextrans; Dideoxynucleosides; Female; Fluorescein-5-isothiocyanate; Heterocyclic Compounds, 3-Ring; Hippocampus; HIV Infections; HIV-1; Lamivudine; Mice; Mice, Transgenic; Models, Biological; Morphine; Neurocognitive Disorders; Oxazines; Piperazines; Pyridones; tat Gene Products, Human Immunodeficiency Virus	2019

Article

Year

Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder.

Assay and drug development technologies, 2019, Volume: 17, Issue:7

Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Female; HIV Infections; Injections, Intraperitoneal; Lamivudine; Neurocognitive Disorders; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tissue Distribution; Zidovudine

2019

HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Journal of neurovirology, 2019, Volume: 25, Issue:4

Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Corpus Striatum; Dextrans; Dideoxynucleosides; Female; Fluorescein-5-isothiocyanate; Heterocyclic Compounds, 3-Ring; Hippocampus; HIV Infections; HIV-1; Lamivudine; Mice; Mice, Transgenic; Models, Biological; Morphine; Neurocognitive Disorders; Oxazines; Piperazines; Pyridones; tat Gene Products, Human Immunodeficiency Virus

2019